VEL-101 (pegrizeprument)
Prevention of acute rejection in solid organ transplant recipients (Orphan Designation for liver transplant)
Phase 1Active
Key Facts
Indication
Prevention of acute rejection in solid organ transplant recipients (Orphan Designation for liver transplant)
Phase
Phase 1
Status
Active
Company
About Veloxis Pharmaceuticals
Veloxis Pharmaceuticals is a U.S.-based, Asahi Kasei-owned company specializing in novel immunosuppressive therapies for solid organ transplant recipients. Its lead asset, VEL-101 (pegrizeprument), is a Phase 1 subcutaneous CD28 co-stimulation blocker with Orphan Drug Designation for liver transplant rejection, aiming to reduce toxicities of current standards. The company leverages its parent company's global network and resources to advance its pipeline while maintaining an agile, efficient operational model focused solely on the transplant therapeutic area.
View full company profile